Driehaus Capital Management LLC Revance Therapeutics, Inc. Transaction History

Driehaus Capital Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$24.7 - $37.61 $4.98 Million - $7.58 Million	201,566 New	201,566 $5.1 Million
Q4 2021 Feb 14, 2022	SELL	$12.46 - $27.87 $4.75 Million - $10.6 Million	-381,302 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$25.78 - $33.21 $4.49 Million - $5.79 Million	174,294 Added 84.2%	381,302 $10.6 Million
Q2 2021 Aug 16, 2021	SELL	$26.8 - $31.84 $90,986 - $108,096	-3,395 Reduced 1.61%	207,008 $6.14 Million
Q1 2021 May 17, 2021	SELL	$24.03 - $29.97 $385,969 - $481,378	-16,062 Reduced 7.09%	210,403 $5.88 Million
Q4 2020 Feb 16, 2021	SELL	$23.41 - $28.34 $8.35 Million - $10.1 Million	-356,898 Reduced 61.18%	226,465 $6.42 Million
Q3 2020 Nov 16, 2020	SELL	$23.23 - $34.3 $3.86 Million - $5.7 Million	-166,067 Reduced 22.16%	583,363 $14.7 Million
Q2 2020 Aug 14, 2020	BUY	$12.6 - $26.55 $109,015 - $229,710	8,652 Added 1.17%	749,430 $18.3 Million
Q1 2020 May 15, 2020	BUY	$12.46 - $27.81 $1.06 Million - $2.36 Million	84,765 Added 12.92%	740,778 $11 Million
Q4 2019 Feb 12, 2020	BUY	$11.66 - $20.15 $7.65 Million - $13.2 Million	656,013 New	656,013 $10.6 Million

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Driehaus Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Driehaus Capital Management LLC with notifications on news.